BARCELONA, Spain, April 25, 2015 /PRNewswire/ -- With the
introduction of Elekta's new Leksell Gamma Knife® Icon™, the
benefits of precision cranial radiosurgery are now available for
more patients with a wider variety of tumor types and sizes. This
latest generation stereotactic radiosurgery system for the brain,
integrates advanced motion management, dose delivery and imaging
technologies, significantly increasing the versatility of Gamma
Knife radiosurgery. Elekta unveiled Leksell Gamma Knife Icon today
at the 3rd ESTRO Forum in Barcelona.
"This is great news for patients," says Niklas Savander, Elekta
President and CEO. "With the new functionality in Leksell
Gamma Knife Icon, doctors will have even greater flexibility in how
radiosurgery is delivered, in addition to more assurance about the
radiation dose and how accurately it's targeted. This new Leksell
Gamma Knife will further strengthen our leading position in
radiosurgery and hopefully address some of the more complex brain
disorders from which many people suffer."
Icon provides this increased flexibility by allowing physicians
to choose either frame-based or frameless methods to immobilize the
patient's head, in addition to the option to perform the treatment
in a single session or multiple sessions (fractions or
hypofractionation). The system even enables clinicians to choose
the degree of precision needed for each patient's case – ranging
from traditional radiosurgery accuracy to ultra-precise
microradiosurgery.
"With Leksell Gamma Knife Icon, we expect two major changes,"
says Professor Jean Regis, a
neurosurgeon and Gamma Knife program director at University
Hospital La Timone (Marseilles, France). "First, the system will increase
indications, in the sense that we will be able do more
hypofractionation. The second great benefit of Icon is the ability
to do true adaptive radiosurgery both interfraction and
intrafraction. It has the capacity to detect and measure position
changes – to automatically propose dose planning adaptation – while
providing the operator with an estimate of the influence of these
corrections for validation."
Elekta developed Icon to be the preferred modality to treat
almost any intracranial target. It offers new functionality
familiar to radiation oncologists, such as cone beam CT, which
should help increase the adoption of radiosurgery. By being
attractive to more clinics, more patients will have access to the
benefits of precision cranial radiosurgery.
Maurits Wolleswinkel, Executive
Vice President Neuroscience at Elekta, says: "By giving doctors
greater clinical flexibility and precision, it should also give
patients greater confidence and peace of mind. This system is
intended to give physicians the ability and confidence to treat
virtually any pathology found in the brain with the highest
precision and certainty, and the efficient workflows that will
allow them to do this every day in the clinic," he says.
Leksell Gamma Knife Icon is not for sale or distribution in
the US and is not CE marked.
For further information, please contact:
Gert van Santen, Group Vice President Corporate
Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Tobias Bulow, Director Financial
Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make
public in accordance with the Securities Market Act and/or the
Financial Instruments Trading Act. The information was published at
10:15 CET on April 25, 2015.
About Elekta
Elekta is a human care company pioneering
significant innovations and clinical solutions for treating cancer
and brain disorders. The company develops sophisticated,
state-of-the-art tools and treatment planning systems for radiation
therapy, radiosurgery and brachytherapy, as well as workflow
enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence
to both health care providers and patients, Elekta aims to improve,
prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in
over 6,000 hospitals worldwide. Elekta employs around 3,800
employees globally. The corporate headquarters is located in
Stockholm, Sweden, and the company
is listed on NASDAQ Stockholm. Website: www.elekta.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-leksell-gamma-knife-to-benefit-more-patients-with-brain-disease-300072077.html
SOURCE Elekta